178 related articles for article (PubMed ID: 22338177)
21. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.
Gil L; Styczynski J; Dytfeld D; Debski R; Kazmierczak M; Kolodziej B; Rafinska B; Kubicka M; Nowicki A; Komarnicki M; Wysocki M
Anticancer Res; 2007; 27(6B):4021-5. PubMed ID: 18225565
[TBL] [Abstract][Full Text] [Related]
22. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
23. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
24. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Yu C; Friday BB; Yang L; Atadja P; Wigle D; Sarkaria J; Adjei AA
Neuro Oncol; 2008 Jun; 10(3):309-19. PubMed ID: 18445700
[TBL] [Abstract][Full Text] [Related]
26. Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Nie D; Huang K; Yin S; Li Y; Xie S; Ma L; Wang X; Wu Y; Xiao J
Leuk Lymphoma; 2012 Dec; 53(12):2487-95. PubMed ID: 22642934
[TBL] [Abstract][Full Text] [Related]
27. [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Sun QX; Meng FY; Fu YB; Li L; Tian S
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1022-5. PubMed ID: 17666343
[TBL] [Abstract][Full Text] [Related]
28. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
30. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
31. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
32. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
34. Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis.
Zhang J; Chen B; Wu T; Wang Q; Zhuang L; Zhu C; Fan N; Qing W; Ma Y; Xu X
PLoS One; 2015; 10(11):e0142422. PubMed ID: 26544558
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of bortezomib-induced apoptosis by TGF-beta in cultured human Tenon's fibroblasts: contribution of the PI3K/Akt signaling pathway.
Chung EJ; Moon SW; Jung SA; Cho YJ; Kim SW; Lee JH
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6232-7. PubMed ID: 20702821
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Huang J; Ding T; Yang M; Liu H; Sun X; Jin J
Int J Hematol; 2011 Apr; 93(4):482-493. PubMed ID: 21451957
[TBL] [Abstract][Full Text] [Related]
37. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Pitts TM; Morrow M; Kaufman SA; Tentler JJ; Eckhardt SG
Mol Cancer Ther; 2009 Feb; 8(2):342-9. PubMed ID: 19174560
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
39. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Zheng B; Zhou R; Gong Y; Yang X; Shan Q
Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
